Jens C. Hahne
A5034116088- Genetic factors in colorectal cancer
- MicroRNA in disease regulation
- Cancer Genomics and Diagnostics
- Cancer-related molecular mechanisms research
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Circular RNAs in diseases
- Gastric Cancer Management and Outcomes
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Immunotherapy and Biomarkers
- PI3K/AKT/mTOR signaling in cancer
- Cancer Cells and Metastasis
- Pancreatic and Hepatic Oncology Research
- Cancer Mechanisms and Therapy
- Esophageal Cancer Research and Treatment
- Peptidase Inhibition and Analysis
- Health and Medical Research Impacts
- Cancer Research and Treatments
- Advanced biosensing and bioanalysis techniques
- RNA Interference and Gene Delivery
- Mathematical Biology Tumor Growth
- RNA modifications and cancer
- Cell Adhesion Molecules Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Metastasis and carcinoma case studies
Institute of Cancer Research
2015-2024
National Institute for Health Research
2024
Cancer Research UK
2017-2024
University of Leicester
2024
NIHR Leicester Biomedical Research Centre
2024
Royal Marsden Hospital
2017-2020
Royal Marsden NHS Foundation Trust
2018
Medical Research Council
2016
University College London
2016
Maastricht University
2016
Cancer organoids to model therapy response are miniature, three-dimensional cell culture models that can be made from primary patient tumors and studied in the laboratory. Vlachogiannis et al. asked whether such “tumor-in-a-dish” approaches used predict drug responses clinic. They generated a live organoid biobank patients with metastatic gastrointestinal cancer who had previously been enrolled phase I or II clinical trials. This allowed authors compare how actually responded Encouragingly,...
Purpose The Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial established perioperative epirubicin, cisplatin, and fluorouracil chemotherapy as a standard of care for patients with resectable esophagogastric cancer. However, identification at risk relapse remains challenging. We evaluated whether pathologic response lymph node status after neoadjuvant are prognostic in treated the MAGIC trial. Materials Methods Pathologic regression was assessed resection...
Sequential profiling of plasma cell-free DNA (cfDNA) holds immense promise for early detection patient progression. However, how to exploit the predictive power cfDNA as a liquid biopsy in clinic remains unclear. RAS pathway aberrations can be tracked monitor resistance anti-EGFR monoclonal antibodies patients with metastatic colorectal cancer. In this prospective phase II clinical trial single-agent cetuximab
Background & AimsCholangiocarcinomas (CCA) are resistant to chemotherapy, so new therapeutic agents needed. We performed a screen identify small-molecule compounds that active against CCAs. Levels of microRNA 21 (MIR21 or miRNA21) increased in investigated whether miRNA21 mediates resistance CCA cells and organoids HSP90 inhibitors.MethodsWe high-throughput 484 those reduced viability 6 human cell lines. tested the effects inhibitors on with disruption MIR21 gene, incubated inhibitors,...
Abstract Purpose: The multi-kinase inhibitor (mKi) regorafenib has demonstrated efficacy in chemorefractory patients with metastatic colorectal cancer (mCRC). However, lack of predictive biomarkers and concerns over significant toxicities hamper the use clinical practice. Experimental Design: Serial liquid biopsies were obtained at baseline monthly until disease progression mCRC treated a phase II trial (PROSPECT-R n = 40; NCT03010722) multicentric validation cohort (n 241). Tissue collected...
Objective Transcribed-ultraconserved regions (T-UCR) are long non-coding RNAs which conserved across species and involved in carcinogenesis. We studied T-UCRs downstream of the Wnt/β-catenin pathway liver cancer. Design Hypomorphic Apc mice ( Apcfl/fl ) thiocetamide (TAA)-treated rats developed dependent hepatocarcinoma (HCC) cholangiocarcinoma (CCA), respectively. T-UCR expression was assessed by microarray, real-time PCR situ hybridisation. Results Overexpression uc.158− could...
Objective Regorafenib demonstrated efficacy in patients with metastatic colorectal cancer (mCRC). Lack of predictive biomarkers, potential toxicities and cost-effectiveness concerns highlight the unmet need for better patient selection. Design Patients RAS mutant mCRC biopsiable metastases were enrolled this phase II trial. Dynamic contrast-enhanced (DCE) MRI was acquired pretreatment at day 15 post-treatment. Median values volume transfer constant (K trans ), enhancing fraction (EF) their...
Anti-angiogenic strategies are emerging as an important tool for the treatment of cancer and inflammatory diseases. In present investigation we isolated several isoflavones from a tempeh (fermented soyabean) extract. The were identified 5,7,4′-trihydroxyisoflavone (genistein), 7,4′-dihydroxyisoflavone (daidzein), 6,7,4′-trihydroxyisoflavone (factor 2), 7,8,4′-trihydroxyisoflavone (7,8,4′-TriOH) 5,7,3′,4′-tetrahydroxyisoflavone (orobol). effects on angiogenesis these evaluated in chicken...
There are limited data on circulating, cell-free, tumour (ct)DNA analysis in locally advanced rectal cancer (LARC). Digital droplet (dd)PCR was used to investigate KRAS/BRAF mutations ctDNA from baseline blood samples of 97 LARC patients who were treated with CAPOX followed by chemoradiotherapy, surgery and adjuvant ± cetuximab a randomised phase II trial. KRAS mutation G12D, G12V or G13D detected the 43% 35% tumours that mutant wild-type for these hotspot mutations, respectively, according...
Although biliary tract cancers (BTCs) are known to have an inflammatory component, a detailed characterisation of immune-related transcripts has never been performed. In these studies, nCounter PanCancer Immune Profiling Panel was used assess the expression 770 in tumour tissues (TTs) and matched adjacent (ATs) resected BTCs. Cox regression analysis Kaplan-Meier methods were correlate findings with relapse-free survival (RFS). The first TT AT exploratory set (n = 22) showed deregulation 39...
<div>AbstractPurpose:<p>We tested whether circulating tumor DNA (ctDNA) changes may be used to assess early response and clinical outcomes in patients with metastatic colorectal cancer (mCRC) undergoing first-line systemic anticancer therapy (SACT).</p>Experimental Design:<p>Eight hundred sixty-two plasma samples were collected 4-weekly from baseline (BL) until disease progression mCRC receiving SACT. ctDNA was using tissue-agnostic next-generation sequencing panels....
<p>Supp Table S2</p>
<p>Supp Table S3</p>
<p>Supp Tables</p>
<p>Supplementary Figures S1-S6</p>
<p>Supp Table S3</p>
<p>Supp Tables</p>
<p>Supp Table S2</p>